Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: BIIB122 225 mg
OTHER: BIIB122-Matching Placebo

Sponsor

Denali Therapeutics Inc.

Collaborators

[object Object]